<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> is characterized by the presence of <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> in plasma of patients with thromboembolic complications </plain></SENT>
<SENT sid="1" pm="."><plain>A major problem in defining the syndrome is that serologic assays to detect <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> have a low specificity </plain></SENT>
<SENT sid="2" pm="."><plain>We recently published a method that specifically detects <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> (LAC) caused by anti-beta(2)-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I antibodies </plain></SENT>
<SENT sid="3" pm="."><plain>Here, we studied the clinical relevance of detecting beta(2)-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I-dependent LAC </plain></SENT>
<SENT sid="4" pm="."><plain>Plasma samples were collected from 198 patients with <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>In those samples with a positive partial thromboplastin time-<z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> (PTT-LA), a modified activated partial thromboplastin time (aPTT)-based LAC test was performed with <z:chebi fb="0" ids="28494">cardiolipin</z:chebi> as confirming agent </plain></SENT>
<SENT sid="6" pm="."><plain>Twenty-five of 58 patients with an aPTT-based LAC were dependent on the presence of anti-beta(2)-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I antibodies </plain></SENT>
<SENT sid="7" pm="."><plain>Presence of beta(2)-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I-dependent LAC was almost completely associated with a history of thromboembolic complications (odds ratio, 42.3; 95% confidence interval, 194.3-9.9) </plain></SENT>
<SENT sid="8" pm="."><plain>An increased frequency of <z:mp ids='MP_0005048'>thrombosis</z:mp> was not found in 33 patients with LAC independent of anti-beta(2)-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I antibodies (odds ratio, 1.6; 95% confidence interval, 3.9-0.8) </plain></SENT>
<SENT sid="9" pm="."><plain>The use of an LAC assay with <z:chebi fb="0" ids="28494">cardiolipin</z:chebi> as confirming agent strongly improves the detection of patients at risk of <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
<SENT sid="10" pm="."><plain>Our findings suggest that anti-beta(2)-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I antibodies with LAC activity are antibodies that are responsible for the thromboembolic complications in the <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> </plain></SENT>
</text></document>